ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO
June 05, 2022 17:15 ET
|
The Rosen Law Firm PA
NEW YORK, June 05, 2022 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Spero...
Neuronascent Receives FDA Orphan Drug Designation for NNI-351 Treatment of Fragile X Syndrome
June 01, 2022 06:00 ET
|
Neuronascent, Inc.
ROCKVILLE, Md., June 01, 2022 (GLOBE NEWSWIRE) -- Neuronascent Inc, today announced that the U.S. Food and Drug Administration (FDA) granted “Orphan Drug Designation” for the company’s NNI-351...
FDA Acknowledges Ligand Innovation Global’s Application for Emergency Use Authorization of LifeAir/VitaCaeli
March 03, 2022 09:00 ET
|
Forwardly, Inc.
Henderson, NV, March 03, 2022 (GLOBE NEWSWIRE) -- Forwardly, Inc. (OTCMKT: FORW) announced today that its partially owned subsidiary and partner, Ligand Innovation Global (“Ligand”), has received...
OWLT LOSS ALERT: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors with Losses to Secure Counsel Before Important January 18 Deadline in Securities Class Action – OWLT
December 28, 2021 18:15 ET
|
The Rosen Law Firm PA
NEW YORK, Dec. 28, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds: (a) purchasers of the securities of Owlet, Inc. (NYSE: OWLT) between March 31, 2021 and...
OWLT NOTICE: ROSEN, TRUSTED NATIONAL TRIAL COUNSEL, Encourages Owlet, Inc. Investors to Inquire About Class Action Investigation – OWLT
October 19, 2021 17:19 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Owlet, Inc....
Processa Pharmaceuticals Cleared by FDA to Proceed with Phase 2a Trial for the Treatment of Gastroparesis
October 12, 2021 08:30 ET
|
Processa Pharmaceuticals, Inc.
HANOVER, MD, Oct. 12, 2021 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the “Company”), a clinical-stage biopharmaceutical company developing products to improve...
ROSEN, TOP RANKED GLOBAL INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – NNOX
October 07, 2021 16:37 ET
|
The Rosen Law Firm PA
NEW YORK, Oct. 07, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Nano-X...
Biofrontera provides update on clinical developments
June 22, 2021 09:00 ET
|
Biofrontera AG
Leverkusen, Germany, June 22, 2021 (GLOBE NEWSWIRE) -- Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F) (the “Company”), an international biopharmaceutical company, today provides an...
ProPhase Labs Reports First Quarter 2021 Financial Results and Announces $0.30 Special Cash Dividend
May 13, 2021 16:05 ET
|
ProPhase Labs, Inc.
First Quarter 2021 Revenue Increases 709% to $15.3 Million Driven by New Diagnostic Services Business Gross Profit Increases to $8.9 Million With Net Income of $1.1 Million or $0.07 Per Share ...
Corbus Pharmaceuticals Reports Last Subject Visit in DETERMINE Phase 3 Study of Lenabasum for Treatment of Dermatomyositis
March 30, 2021 08:05 ET
|
Corbus Pharmaceuticals Holdings, Inc.
Topline data on schedule for Q2 2021Dermatomyositis is a rare and life-threatening autoimmune disease characterized by skin and muscle inflammation, and affects ~80,000 people in North America, EU,...